Venkitasamy Kesavan

This inventor holds 15 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Oligonucleotide Chemistry. Top assignees: Alnylam Pharmaceuticals, Inc., Epix Delaware, Inc., Predix Pharmaceuticals Holdings, Inc.. Active years: 2006-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Venkitasamy Kesavan. Retrieved from https://idiyas.com/inventor/venkitasamy-kesavan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 86.7

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.4

ph-index = 8

Forward Citations = 354(Granted Patents)

Location History:

Woburn, MA (US) (2006 - 2013)
Cambridge, MA (US) (2014 - 2022)

Company Filing History:

13 out of 467

Alnylam Pharmaceuticals, Inc.

Predix Pharmaceuticals Holdings, Inc.

patent

Years Active: 2006-2022

Loading Chart...

Areas of Expertise:

iRNA Agents

Oligonucleotides

Ligand-Conjugated Monomers

Chemically Modified Oligonucleotides

2-Arylpropyl Moiety

Piperidinylamino Compounds

Single-Stranded Oligonucleotides

Double-Stranded Oligonucleotides

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11312957 - Modified iRNA agents (2022-04-26),

2. 10676740 - Modified iRNA agents (2020-06-09),

3. 9453222 - Ligand-conjugated monomers (2016-09-27),

4. 9394540 - Modified iRNA agents (2016-07-19),

5. 8957223 - Ligand-conjugated monomers (2015-02-17),

6. 8796436 - Modified iRNA agents (2014-08-05),

7. 8507661 - Modified iRNA agents (2013-08-13),

8. 8470988 - Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety (2013-06-25),

9. 8404862 - Ligand-conjugated monomers (2013-03-26),

10. 8017763 - Chemically modified oligonucleotides (2011-09-13),

11. 7745608 - Modified iRNA agents (2010-06-29),

12. 7626014 - Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety (2009-12-01),

13. 7612078 - Piperidinylamino-thieno[2,3-D] pyrimidine compounds (2009-11-03),

14. 7582744 - Chemically modified oligonucleotides (2009-09-01),

15. 7030240 - Piperidinylamino-thieno[2,3-d] pyrimidine compounds (2006-04-18),

Title: The Innovative Contributions of Venkitasamy Kesavan

Introduction

Venkitasamy Kesavan, a distinguished inventor based in Woburn, MA, has made remarkable strides in the field of biotechnology and pharmaceuticals. With an impressive portfolio of 15 patents, his work primarily revolves around innovative iRNA agents, which have significant implications for therapeutic applications.

Latest Patents

Among his notable inventions are the modified iRNA agents. These agents include a unique monomer in which the ribose moiety has been substituted with a different moiety. This substitution enhances the ability to modulate properties of the iRNA agents, allowing for beneficial modifications. For instance, the non-ribose moiety can be used as a point for tethering ligands or lipophilic entities, such as cholesterol. Furthermore, his patents encompass various methods for creating and utilizing these modified iRNA agents, thereby contributing to advancements in gene regulation and potential treatments for diseases.

Career Highlights

Venkitasamy has held influential positions in reputable companies, including Alnylam Pharmaceuticals and Predix Pharmaceuticals Holdings. His roles in these organizations have enabled him to translate innovative ideas into practical solutions within the biopharmaceutical sector, further demonstrating his expertise and commitment to advancing medical science.

Collaborations

Throughout his career, Venkitasamy has collaborated with notable colleagues, including Muthiah Manoharan and Kallanthottathil G Rajeev. These collaborations have likely fostered a dynamic exchange of ideas and expertise, enriching his research and innovation efforts in the field.

Conclusion

Venkitasamy Kesavan stands out as a leading inventor in the biotechnology realm, with a strong focus on developing modified iRNA agents that hold promise for future medical therapies. His patents and collaborations with other experts highlight the significant impact of his work on the advancement of therapeutic technologies. The contributions that he continues to make will undoubtedly influence the field for years to come.

Profile summary based on public USPTO records.